Cargando…

Neurocognitive impairment and patient–proxy agreement on health-related quality of life evaluations in recurrent high-grade glioma patients

PURPOSE: The rate of missing data on patient-reported health-related quality of life (HRQOL) in brain tumor clinical trials is particularly high over time. One solution to this issue is the use of proxy (i.e., partner, relative, informal caregiver) ratings in lieu of patient-reported outcomes (PROs)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caramanna, Ivan, Klein, Martin, van den Bent, Martin, Idbaih, Ahmed, Wick, Wolfgang, Taphoorn, Martin J. B., Dirven, Linda, Bottomley, Andrew, Reijneveld, Jaap C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546946/ https://www.ncbi.nlm.nih.gov/pubmed/35982202 http://dx.doi.org/10.1007/s11136-022-03197-w

Ejemplares similares

Impact of neurocognitive deficits on patient–proxy agreement regarding health-related quality of life in low-grade glioma patients
por: Ediebah, Divine E., et al.
Publicado: (2016)

Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101
por: Caramanna, Ivan, et al.
Publicado: (2022)

Do neurocognitive impairments explain the differences between brain tumor patients and their proxies when assessing the patient’s IADL?
por: Oort, Quirien, et al.
Publicado: (2022)

Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide
por: Koekkoek, Johan A. F., et al.
Publicado: (2015)

Health-related quality of life in high-grade glioma patients
por: Dirven, Linda, et al.
Publicado: (2014)

Long-term wellbeing and neurocognitive functioning of diffuse low-grade glioma patients and their caregivers: A longitudinal study spanning two decades
por: Boele, Florien W, et al.
Publicado: (2022)

Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period
por: Coomans, Marijke B, et al.
Publicado: (2022)

Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients
por: Dirven, Linda, et al.
Publicado: (2021)

Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?
por: Coomans, Marijke B, et al.
Publicado: (2019)

Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients
por: Coomans, Marijke B, et al.
Publicado: (2020)

Disturbed functional brain networks and neurocognitive function in low-grade glioma patients: a graph theoretical analysis of resting-state MEG
por: Bosma, Ingeborg, et al.
Publicado: (2009)

Withdrawal of antiepileptic drugs in glioma patients after long-term seizure freedom: design of a prospective observational study
por: Koekkoek, Johan A F, et al.
Publicado: (2014)

Effect of antiepileptic drugs in glioma patients on self-reported depression, anxiety, and cognitive complaints
por: van der Meer, Pim B., et al.
Publicado: (2021)

Withdrawal of antiepileptic drugs in patients with low grade and anaplastic glioma after long-term seizure freedom: a prospective observational study
por: Kerkhof, M., et al.
Publicado: (2019)

Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033
por: Klein, Martin, et al.
Publicado: (2020)

Evaluation of the Hippocampal Normal Tissue Complication Model in a Prospective Cohort of Low Grade Glioma Patients—An Analysis Within the EORTC 22033 Clinical Trial
por: Jaspers, Jaap, et al.
Publicado: (2019)

Research Objectives, Statistical Analyses and Interpretation of Health-Related Quality of Life Data in Glioma Research: A Systematic Review
por: Coomans, Marijke B., et al.
Publicado: (2020)

The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033
por: Bady, Pierre, et al.
Publicado: (2018)

Antiepileptic drug treatment in the end-of-life phase of glioma patients: a feasibility study
por: Koekkoek, Johan A. F., et al.
Publicado: (2015)

The effectiveness of antiepileptic drug treatment in glioma patients: lamotrigine versus lacosamide
por: van Opijnen, Mark P., et al.
Publicado: (2021)

Does early resection of presumed low-grade glioma improve survival? A clinical perspective
por: Wijnenga, Maarten M. J., et al.
Publicado: (2017)

Effectiveness of Antiseizure Medication Duotherapies in Patients With Glioma: A Multicenter Observational Cohort Study
por: van der Meer, Pim B., et al.
Publicado: (2022)

First‐line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acid
por: van der Meer, Pim B., et al.
Publicado: (2021)

Effectiveness of Antiseizure Medication Triple Therapy in Patients With Glioma With Refractory Epilepsy: An Observational Cohort Study
por: van der Meer, Pim B., et al.
Publicado: (2023)

Evaluation of the content coverage of questionnaires containing basic and instrumental activities of daily living (ADL) used in adult patients with brain tumors
por: Oort, Quirien, et al.
Publicado: (2019)

Retention rates of antiepileptic drugs in glioma patients: the most appropriate outcome
por: van der Meer, Pim B, et al.
Publicado: (2020)

Impact of timing of antiseizure medication withdrawal on seizure recurrence in glioma patients: a retrospective observational study
por: van der Meer, Pim B., et al.
Publicado: (2023)

Advance Care Planning in Glioblastoma Patients
por: Fritz, Lara, et al.
Publicado: (2016)

Is the EORTC QLQ‐C30 emotional functioning scale appropriate as an initial screening measure to identify brain tumour patients who may possibly have a mood disorder?
por: Oort, Quirien, et al.
Publicado: (2022)

Longitudinal proxy measurements in multiple sclerosis: patient-proxy agreement on the impact of MS on daily life over a period of two years
por: van der Linden, Femke AH, et al.
Publicado: (2008)

Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling
por: Coomans, Marijke B, et al.
Publicado: (2020)

Current treatment of low grade gliomas
por: van den Bent, Martin J., et al.
Publicado: (2012)

Individual changes in neurocognitive functioning and health-related quality of life in patients with brain oligometastases treated with stereotactic radiotherapy
por: van der Meer, Pim B., et al.
Publicado: (2018)

First‐line levetiracetam versus enzyme‐inducing antiseizure medication in glioma patients with epilepsy
por: van der Meer, Pim B., et al.
Publicado: (2022)

Evaluating the lack of impact of the e-health application Oncokompas on outcomes in incurably ill cancer patients
por: Dirven, Linda, et al.
Publicado: (2022)

Efficacy of antiepileptic drugs in glioma patients with epilepsy: a systematic review
por: de Bruin, Marjolein E, et al.
Publicado: (2021)

Advance care planning in glioblastoma patients: development of a disease-specific ACP program
por: Fritz, Lara, et al.
Publicado: (2019)

On high‐risk, low‐grade glioma: What distinguishes high from low?
por: Geurts, Marjolein, et al.
Publicado: (2018)

Prediagnostic presentations of glioma in primary care: a case–control study
por: Peeters, Marthe CM, et al.
Publicado: (2019)

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
por: Weller, Michael, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1rmfruh8br6lqkrg266i499j7d